class Gaucher therapeutic Gaucher disease
patients
Fabry disease
course of disease
neuronopathic Gaucher forms
Potent GCS inhibitors
Tay-Sachs disease
potent dual GCS
phase
clinical development
substrate reduction therapy
inhibitors of glucosylceramide synthase
substrate of GBA
non-neuronopathic
therapeutic agents
lead molecule
attractive lead
clinical candidate
administration of recombinant GBA1
causative storage materials
enzyme replacement therapy
GD
best
GBA2 inhibitor
globosides
Eliglustat
treatment
ERT
GM1 gangliosidosis
GlcCer
deficient activity of acid glucosylceramidase
autosomal recessive disorder
ceramide mimic
neurological symptoms
iminosugar
Zavesca
gangliosides
SRT
higher glycosphingolipids
packet
BiPheDNM
Figure C
relevant data
tools
unmet medical need
pharmaceutical partner
types
proof of concept project